TENX — Tenax Therapeutics Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates TENX Bearish with a Setup Score of 37, net conviction 42, actionability 32. How the Setup Score works →

Total Setup Score37
Directional BiasBearish
Net Conviction42
Actionability32 (in range)

Key signals behind this score

About Tenax Therapeutics Inc

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatmen… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$1.87
Market Cap$69.6M
Float30.8M
Shares Outstanding37.4M
P/E (Forward)0.30
Price/Sales (TTM)414.72
vs. Analyst Target+571.4% to analyst PT
Dividend RateNone
Analyst Target Price$12.56 (10 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$9.9M -$114,748 -$9.7M
2021 N/A -$32.5M -$108,982 -$32.4M
2022 N/A -$11.0M -$113,332 -$10.9M
2023 N/A -$7.7M -$7,570 -$7.7M
2024 N/A -$17.6M N/A -$17.6M
2025 N/A -$52.6M N/A -$52.6M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Sep 2025 N/A -$15.8M
Dec 2025 N/A -$15.5M
Mar 2026 N/A -$15.7M
Jun 2026 N/A -$17.8M

Ownership & Float

Insider Ownership0.2%
Institutional Ownership108.2%
Short Float30.1%
% of All Funds Holding1.26%
Number of Funds Holding111

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$3.05Near-term / short-term trend
Weekly40-Week SMA$10.84Medium-term trend
Weekly80-Week SMA$8.92Cyclical trend (business cycle)
Weekly200-Week SMA$19.59Secular trend (multi-year)
Monthly10-Month SMA$9.93Near-term monthly trend
Monthly20-Month SMA$8.61Medium-term monthly trend
Monthly40-Month SMA$9.63Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$13.70 resistance 6.85x 1 months ago

Historical Earnings Reactions (103 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.15% 0.00% 41.75% 9.59% -19.48%
1 Day -0.72% 0.00% 43.69% 20.83% -18.55%
1 Week -0.47% 0.00% 47.57% 55.17% -89.96%
2 Weeks -0.73% -2.09% 37.86% 74.71% -87.52%
1 Month 1.09% -2.08% 41.18% 177.78% -70.44%

Next earnings: November 11, 2026 (31 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-2.4%31.3%32
Feb13.4%28.1%32
Mar9.1%40.6%32
Apr-3.6%31.3%32
May0.9%42.4%33
Jun-6.0%33.3%33
Jul0.7%39.4%33
Aug-3.1%33.3%33
Sep-6.5%21.2%33
Oct0.9%46.9%32
Nov6.7%43.8%32
Dec0.4%46.9%32

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.22% 39.0% 1537
Tuesday 0.02% 38.9% 1680
Wednesday 0.36% 42.0% 1678
Thursday 0.07% 38.9% 1646
Friday 0.42% 41.5% 1639

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 108.2%

Insider Transactions — Smart Summary

Total insider ownership: 0.2%

12-Month Insider Activity Summary

Total Filings11
Net Value+$205,646.753
Net Shares Change2,788,323
% of Float9.1%
C-Suite Filings6
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
ADAR1 Capital Management, LLC +$4.8M 3 3 buy
Doogan Declan +$101,760 1 1 buy
Rich Stuart Chief Medical Officer +$96,414.25 2 4 buy
MCGAULEY THOMAS Interim CFO +$58,163.8 1 2 buy
Giordano Christopher Thomas CEO +$40,087.578 2 2 buy
STAAB THOMAS R II Chief Financial Officer +$10,981.125 1 1 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-11-19 – 2025-11-20 3 3 +$93,108.397 2 C-suite
2026-09-08 – 2026-09-17 4 4 +$1.7M 2 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-09-15 STAAB THOMAS R II Chief Financial Officer +$10,981.125 Transaction at $1.94, now -3.4%
2026-09-15 Giordano Christopher Thomas CEO +$20,087.69 Transaction at $1.85, now +1.0%
2026-09-17 Doogan Declan +$101,760 Transaction at $1.92, now -2.6%
2026-09-08 ADAR1 Capital Management, LLC +$1.6M Transaction at $1.78, now +4.9%
2026-09-02 ADAR1 Capital Management, LLC +$1.4M Transaction at $1.79, now +4.3%
2026-08-24 ADAR1 Capital Management, LLC +$1.8M Transaction at $1.77, now +5.7%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Tenax Therapeutics Inc (TENX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for TENX on Trend Edge →